Trustmark National Bank Trust Department’s Alexion Pharmaceuticals ALXN Stock Holding History

Trustmark National Bank Trust Department’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-2,075	Closed	-$344K	–	337
2014 Q3	$344K	Hold	2,075	–	–	0.05%	267
2014 Q2	$325K	Sell	2,075 -2,000	-49%	-$316K	0.04%	282
2014 Q1	$620K	Hold	4,075	–	–	0.07%	215
2013 Q4	$542K	Hold	4,075	–	–	0.06%	219
2013 Q3	$474K	Hold	4,075	–	–	0.06%	219
2013 Q2	$376K	Buy	+4,075	New	+$393K	0.05%	239

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trustmark National Bank Trust Department's ALXN Position: Q4 2014 in Review

Trustmark National Bank Trust Department sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 2,075 shares — an estimated $344K sold.

Trustmark National Bank Trust Department first reported a position in ALXN in Q2 2013 and held it in 6 quarters. The position peaked at $620K in Q1 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

Trustmark National Bank Trust Department reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Trustmark National Bank Trust Department sold 2,075 Alexion Pharmaceuticals shares in Q4 2014, an estimated $344K.
Trustmark National Bank Trust Department first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Trustmark National Bank Trust Department's Alexion Pharmaceuticals position peaked at $620K in Q1 2014.
579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Trustmark National Bank Trust Department's 13F filing for Q4 2014, filed 17 Feb 2015.